BMJ case reports, 2014-06, Vol.2014, p.bcr2013202515
2014
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Delayed onset panuveitis following intravitreal aflibercept injection
- Ist Teil von
- BMJ case reports, 2014-06, Vol.2014, p.bcr2013202515
- Ort / Verlag
- England: BMJ Publishing Group LTD
- Erscheinungsjahr
- 2014
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Aflibercept has been listed on the Australian Pharmaceutical Benefit Scheme for the past year for neovascular age-related macular degeneration. Since that time there have not been any reports of delayed onset panuveitis. We present two cases of anterior and posterior uveitis that have occurred 4 weeks or more after first intravitreal injection of aflibercept. Both patients had received other vascular endothelial growth factor inhibitors prior to aflibercept administration without signs of inflammation and both cases had sterile endophthalmitis. On resolution of the inflammation the patients were recommenced on ranibizumab without further incident.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1757-790XeISSN: 1757-790XDOI: 10.1136/bcr-2013-202515Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4069789
- Format
- –
- Schlagworte
- 80 Years, Aged, Aged, 80 and over, Angiogenesis Inhibitors - administration & dosage, Angiogenesis Inhibitors - adverse effects, Antigens, Australasia, Cataracts, Female, Glaucoma, Herpes viruses, Humans, Inflammation, Injections, Intravitreal Injections, Iodine, Macular degeneration, Macular Degeneration - drug therapy, Male, Panuveitis - chemically induced, Receptors, Vascular Endothelial Growth Factor - administration & dosage, Receptors, Vascular Endothelial Growth Factor - adverse effects, Recombinant Fusion Proteins - administration & dosage, Recombinant Fusion Proteins - adverse effects, Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions, Vascular endothelial growth factor, Visual acuity, White